TP53 and cancer: Barakat et al. designed a new lead compound based on the core structure of spirooxindole clubbed with a benzimidazole moiety that has been shown to be highly effective against cancer cells targeted as inhibitors of protein–protein interaction between MDM2-p53 genes.